Less than 10% of individuals that would benefit from weight-loss injections like Wegovy are able to get them, warns the World Health Organization as it publishes its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide currently obese, it is advocating for increased and just availability to GLP-1 medication.
Based on forecasts, over two billion could be obese by 2030 without intervention.
"Our new guidance recognises that excess weight is a long-term condition that can be treated with holistic and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major hurdles to widespread access to the treatments that can assist patients in reducing substantial weight, says the body.
Weight-Loss Drug Supply Crisis
Despite the current most favorable case, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of eligible patients, as stated by the WHO.
The advice encourages countries and companies to widen access, via measures such as licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Jabs Operate
The injections replicate a biological compound to reduce digestion speed, curb appetite and enhance the sense of being full so individuals eat less.
People usually see weight reduction within a few weeks of commencing the weekly injections.
Studies indicates users may see weight return a year later of stopping the treatment, as their usual hunger return.
To be above a healthy weight raises your chance for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight affects people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
